Rosanna Sutherby, Pharm.D.

Articles

For Atopic Dermatitis Treatment, an Abundance of Options

May 18, 2022

Article

Across the globe, new drugs — injections, topical and oral — are being developed to help patients with atopic dermatitis.

New Target Discovered for Non-Type 2 Inflammation in Severe Asthma

May 17, 2022

Article

Genentech researchers identify oncostatin M as a protein that may be responsible for the severe airway inflammation seen in patients with noneosinophilic asthma.

Dupixent Improves Severe Asthma Symptoms in a Real-World Setting, but Switching May Require Eosinophil Monitoring

May 16, 2022

Article

Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%. There were some reports of adverse events associated with high eosinophil levels in patients who switched to Dupixent after taking a different biologic.

Several Biologics To Treat Severe Asthma Can Be Self-Administered at Home — Patients Prefer It

May 12, 2022

Article

Xolair (omalizumab), Fasenra (benralizumab), Dupixent (dupilumab) and Nucala (mepolizumab) can now be self-administered.

Multiple Sclerosis - Some Drugs New, Some Tried-and-True

April 10, 2022

Article

The race is on to be the first-approved Bruton tyrosine kinase inhibitor. Meanwhile, trials are underway to test statins and metformin as treatments for multiple sclerosis.

Fourth Shot is Recommended for the Immunocompromised

March 10, 2022

Article

Getting boosted is now the rule, not the exception, when it comes to COVID-19 vaccination recommendations. The CDC now recommends that everyone, ages 12 and older, get a dose of an mRNA COVID-19 vaccine, either Pfizer’s or Moderna’s. For people who have gotten the two-shot Pfizer or Moderna series, the booster is their third jab. For those who got the single-dose Johnson & Johnson vaccine, it is the second.